NHS Greater Glasgow and Clyde

nhsggc.org.uk

Total trials

217

Active

31

Phase 3

9

Total enrollment

169,204

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Norepinephrine1
NanO2TM1
Ixekizumab2
Anifrolumab1
Secukinumab1
Bimekizumab1
Tirzepatide1

Next readouts

  • 2025-03-17
  • 2026-07-31
  • 2026-11
  • 2027-02-28
  • 2028-02

Top conditions

  • Heart Failure14
  • Stroke13
  • Cardiovascular Diseases10
  • Obesity6
  • Rheumatoid Arthritis6
  • Insomnia5
  • Crohn Disease5
  • Spinal Cord Injuries5

Frequently asked questions about NHS Greater Glasgow and Clyde

How many clinical trials does NHS Greater Glasgow and Clyde have on ClinicalTrials.gov?
NHS Greater Glasgow and Clyde is listed as the lead sponsor on 217 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of NHS Greater Glasgow and Clyde's trials are in Phase 3?
9 of NHS Greater Glasgow and Clyde's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does NHS Greater Glasgow and Clyde focus on?
NHS Greater Glasgow and Clyde's most-studied conditions on ClinicalTrials.gov are Heart Failure, Stroke, Cardiovascular Diseases, Obesity, Rheumatoid Arthritis.
When are NHS Greater Glasgow and Clyde's next clinical trial readouts?
NHS Greater Glasgow and Clyde has 5 upcoming primary-completion readouts tracked here; the soonest is “Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue”, expected around 2025-03-17.